• Explore /
  • Poster
  • / NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).

NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Florian Guisier

Department of Pneumology, Rouen University Hospital, Rouen, France

Florian Guisier , Jaafar Bennouna , Alexander I. Spira , Dong-Wan Kim , Byoung Yong Shim , Houssein Abdul Sater , Italia Grenga , Swapnil S Parmar , Agata A. Bielska , Alula Yohannes , Raymond Mager , Oday Hamid , Lara McGrath , Yun He , Yee Soo-Hoo , Rakesh Kumar , Jonathan Spicer , Patrick M. Forde , Tina Cascone

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT05061550

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS8604)

DOI

10.1200/JCO.2023.41.16_suppl.TPS8604

Abstract #

TPS8604

Poster Bd #

228b

Abstract Disclosures

Similar Posters

First Author: Sacha Rothschild

First Author: Diane Damotte

First Author: Fabrice Barlesi

First Author: Aaron Scott Mansfield